Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment
| Autor: | E. Feyles, Monia Marchetti, F. Zallio, Ezio Ferroglio, Alberto Biglino, E. Concialdi, A. Casabianca |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Antiprotozoal Agents Antineoplastic Agents Polymerase Chain Reaction Serology Antibodies Monoclonal Murine-Derived Immunocompromised Host Fatal Outcome Bone Marrow Recurrence Amphotericin B medicine Humans Leishmania infantum Aged medicine.diagnostic_test business.industry Lymphoma Non-Hodgkin Leishmaniasis General Medicine medicine.disease Dermatology Lymphoma Non-Hodgkin's lymphoma Bone marrow examination Infectious Diseases Visceral leishmaniasis Italy Immunology Monoclonal Leukocytes Mononuclear Leishmaniasis Visceral Female Rituximab business Polymorphism Restriction Fragment Length medicine.drug |
| Zdroj: | Infection. 39:375-378 |
| ISSN: | 1439-0973 0300-8126 |
| DOI: | 10.1007/s15010-011-0109-5 |
| Popis: | Both the presentation and clinical course of visceral leishmaniasis (VL) may be atypical in immunosuppressed subjects, often resulting in delayed diagnosis and treatment. We describe a case of VL characterized by negative serologic testing, a relapsing course, and a fatal outcome 2 years after the patient had been successfully treated for non-Hodgkin's lymphoma with rituximab. Diagnosis of VL may be further delayed or even missed in patients treated with drugs that interfere with specific antibody production unless specific diagnostic methods, such as bone marrow examination and parasite DNA amplification/detection, are routinely employed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink